Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Catastrophic Coverage: Manufacturers Could Agree To Increased ‘Liability’

Executive Summary

But drug makers want their financial contribution to go toward reducing beneficiary costs, not to replace plans’ insurance risk, according to comments submitted to two House committees on draft legislation.

You may also be interested in...



Medicare Price Inflation Rebates, Part D ‘Redesign’ Proposed In Senate Finance Bill

Price inflation rebates are expected to generate $50bn in savings over 10 years, according to the Congressional Budget Office.

Part D Cost Sharing Cap Offered In Draft US House Bill, But Not How To Pay For It

Biopharma manufacturers might not like the cost offsets that would cover the out-of-pocket maximum for patients in Medicare's drug program; committees seek comment on range of issues.

Medical Benefit, Hospital Drugs Exempt From Detailed Cost, Coverage Reporting In Final Rule

The most detailed US reporting requirements regarding prescription drug costs and coverage will target medicines reimbursed under the retail pharmacy benefit.

Topics

Related Companies

UsernamePublicRestriction

Register

PS125434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel